Dr. Heng Zhou, Early Oncology Statistics group, Merck

Dr. Heng Zhou is a Principal Scientist in Early Oncology Statistics group at Merck, supporting phase 1-3 oncology clinical trials. Prior to joining Merck, he earned Ph.D. in Biostatistics from MD Anderson Cancer Center. His expertise is in oncology clinical trial design, with research focus in innovative Bayesian adaptive designs in phase I/II clinical trials, master protocol trial designs, adaptive phase 2/3 designs, etc.